October 2, 2021

During an interview, Yi-Bin Chen, MD, an investigator of the REACH trials, discussed acute and chronic graft-versus-host disease and treatment options.

During an interview,Raymond U. Osarogiagbon, MD, discussed long-term care and outcome disparities of lung cancer in the United States.

In an interview with Targeted Therapies in Oncology, Nicholas J. Robert, MD, discussed what the results to date of the MYLUNG study mean for patients with non–small cell lung cancer.

For older patients with acute lymphoblastic leukemia, traditional chemotherapy approaches have largely failed.

A significant proportion of patients worldwide live disease-free for a decade or longer following first-line therapy, with various approaches suggesting that there may be pathways to develop approaches for a cure for at least a subset of patients

Neoadjuvant osimertinib may lead to a better mechanistic understanding of what drives incomplete response and residual disease for patients with EGFR-mutant NSCLC. according to Collin M. Blakely, MD, PhD.

Data continue to support the use of RET inhibitors is patients with RET fusion-positive non–small cell lung cancer.

Management of relapsed or refractory disease is a highly relevant topic for patients with mantle cell lymphoma and the clinicians who treat them.

Following the FDA approval of sotorasib for the treatment of KRAS G12C-positive non–small cell lung cancer, there is a great deal of interest in the KRAS inhibitor and its potential benefit.

Flexible patient-focused approaches may increase clinical trial accessibility and enrollment in international lung cancer clinical trials beyond the COVID-19 pandemic.

Treatment with alectinib demonstrated survival benefit in patients with non–small cell lung cancer who have resistance to crizotinib, in a retrospective study.

Small cell lung cancer is the most aggressive form of lung cancer and mostly occurs in smokers. Although the disease has proved to be sensitive to chemotherapy and radiation, responses are short and those who relapse have short survival.

Findings from the phase 1/2 trial of mobocertinib show clinical activity in a subset of patients with EGFR exon 20-positive non–small cell lung cancer.

Despite the success of implementing maintenance therapy in other leukemias, the key challenge with administering maintenance therapy in acute myeloid leukemia has been identifying an effective drug.

Single-agent belantamab demonstrated anti-myeloma activity and a manageable safety profile in the DREAMM-2 phase 2 study.

Data from the phase 3 POSEIDON trial were presented during the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.

In chronic lymphocytic leukemia management, many patients do not fall within the category to receive chemoimmunotherapy. However, for high-risk patients, targeted agents are changing the treatment landscape.

Investigators are looking into newer ways of using hypomethylating agents to treat patients with low-risk and high-risk myelodysplastic syndrome.

Although osimertinib has been shown to overcome T790M-mediated mutations in the second-line setting, as with other EGFR tyrosine kinase inhibiors progression on osimertinib is inevitable.

Despite advances with MRD monitoring, further research and practice advances are needed to continue the trend for improving outcomes in patients with acute lymphoblastic leukemia.